Potent inhibition of carcinogen-bioactivating cytochrome P450 1B1 by the p53 inhibitor pifithrin α

Carcinogenesis

Volumn 27, Issue 3, 2006, Pages 656-663

  Sparfel, Lydie ^a   Van Grevenynghe, Julien ^a   Le Vee, Marc ^a   Aninat, Caroline ^a   Fardel, Olivier ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[A]PYRENE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; ETHOXYRESORUFIN DEETHYLASE; ISOENZYME; PIFITHRIN ALPHA; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN INHIBITOR; PROTEIN P53;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CATALYSIS; CELL PROTECTION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA ADDUCT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEUKEMIA CELL; LIVER MICROSOME; MACROPHAGE; MALE; METABOLISM; METABOLITE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; RAT; TOXICOKINETICS;

APOPTOSIS; ARYL HYDROCARBON HYDROXYLASES; BENZO(A)PYRENE; BENZOTHIAZOLES; BREAST NEOPLASMS; CARCINOGENS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; HUMANS; LEUKEMIA; MACROPHAGES; MICROSOMES, LIVER; PROTEIN ISOFORMS; THIAZOLES; TOLUENE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 31744432611     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi256     Document Type: Article

References (35)

1. Zedeck,M.S. (1980) Polycyclic aromatic hydrocarbons: A review. J. Environ. Pathol. Toxicol., 3, 537-567.
2. Hankinson,O. (1995) The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol., 35, 307-340.
3. Melendez-Colon,V.J., Luch,A., Seidel,A. and Baird,W.M. (1999) Cancer initiation by polycyclic aromatic hydrocarbons results from formation of stable DNA adducts rather than apurinic sites. Carcinogenesis, 20, 1885-1891.
4. Komarov,P.G., Komarova,E.A., Kondratov,R.V., Christov-Tselkov,K., Coon,J.S., Chernov,M.V. and Gudkov,A.V. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science, 285, 1733-1737.
5. Komarova,E.A. and Gudkov,A.V. (2000) Suppression of p53: A new approach to overcome side effects of antitumor therapy. Biochemistry (Mosc), 65, 41-48.
6. Chramostova,K., Vondracek,J., Sindlerova,L., Vojtesek,B., Kozubik,A. and Machala,M. (2004) Polycyclic aromatic hydrocarbons modulate cell proliferation in rat hepatic epithelial stem-like WB-F344 cells. Toxicol. Appl. Pharmacol., 196, 136-148.
7. Andrysik,Z., Machala,M., Chramostova,K., Hofmanova,J., Kozubik,A. and Vondracek,J. (2005) Activation of ERK1/2 and p38 kinases by polycyclic aromatic hydrocarbons in rat liver epithelial cells is associated with induction of apoptosis. Toxicol. Appl. Pharmacol., in press.
8. Solhaug,A., Ovrebo,S., Mollerup,S., Lag,M., Schwarze,P.E., Nesnow,S. and Holme,J.A. (2005) Role of cell signaling in B[a]P-induced apoptosis: characterization of unspecific effects of cell signaling inhibitors and apoptotic effects of B[a]P metabolites. Chem. Biol. Interact., 151, 101-119.
9. van Grevenynghe,J., Sparfel,L., Le Vee,M., Gilot,D., Drenou,B., Fauchet,R. and Fardel,O. (2004) Cytochrome P450-dependent toxicity of environmental polycyclic aromatic hydrocarbons towards human macrophages. Biochem. Biophys. Res. Commun., 317, 708-716.
10. Bradford,M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
11. Sparfel,L., Huc,L., Le Vee,M., Desille,M., Lagadic-Gossmann,D. and Fardel,O. (2004) Inhibition of carcinogen-bioactivating cytochrome P450 1 isoforms by amiloride derivatives. Biochem. Pharmacol., 67, 1711-1719.
12. Burke,M.D., Thompson,S., Elcombe,C.R., Halpert,J., Haaparanta,T. and Mayer,R.T. (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol., 34, 3337-3345.
13. Shimada,T., Yamazaki,H., Foroozesh,M., Hopkins,N.E., Alworth,W.L. and Guengerich,F.P. (1998) Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem. Res. Toxicol., 11, 1048-1056.
14. Landers,J.P. and Bunce,N.J. (1991) The Ah receptor and the mechanism of dioxin toxicity. Biochem. J., 276 (Pt 2), 273-287.
15. Solhaug,A., Refsnes,M., Lag,M., Schwarze,P.E., Husoy,T. and Holme,J.A. (2004) Polycyclic aromatic hydrocarbons induce both apoptotic and anti-apoptotic signals in Hepa1c1c7 cells. Carcinogenesis, 25, 809-819.
16. Hoagland,M.S., Hoagland,E.M. and Swanson,H.I. (2005) The p53 inhibitor pifithrin-alpha is a potent agonist of the aryl hydrocarbon receptor. J. Pharmacol. Exp. Ther., 314, 603-610.
17. van Grevenynghe,J., Rion,S., Le Ferrec,E., Le Vee,M., Amiot,L., Fauchet,R. and Fardel,O. (2003) Polycyclic aromatic hydrocarbons inhibit differentiation of human monocytes into macrophages. J. Immunol., 170, 2374-2381.
18. Pliskova,M., Vondracek,J., Vojtesek,B., Kozubik,A. and Machala,M. (2005) Deregulation of cell proliferation by polycyclic aromatic hydrocarbons in human breast carcinoma MCF-7 cells reflects both genotoxic and nongenotoxic events. Toxicol. Sci., 83, 246-256.
19. Ramet,M., Castren,K., Jarvinen,K., Pekkala,K., Turpeenniemi-Hujanen,T., Soini,Y., Paakko,P. and Vahakangas,K. (1995) p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis, 16, 2117-2124.
20. Solhaug,A., Refsnes,M. and Holme,J.A. (2004) Role of cell signalling involved in induction of apoptosis by benzo[a]pyrene and cyclopenta[c,d]pyrene in Hepa1c1c7 cells. J. Cell. Biochem., 93, 1143-1154.
21. Clave,E., Carosella,E.D., Gluckman,E. and Socie,G. (1997) Radiation-enhanced expression of interferon-inducible genes in the KG1a primitive hematopoietic cell line. Leukemia, 11, 114-119.
22. Shimada,T., Hayes,C.L., Yamazaki,H., Amin,S., Hecht,S.S., Guengerich,F.P. and Sutter,T.R. (1996) Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res., 56, 2979-2984.
23. Chun,Y.J. and Kim,S. (2003) Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents. Med. Res. Rev., 23, 657-668.
24. Guengerich,F.P., Chun,Y.J., Kim,D., Gillam,E.M. and Shimada,T. (2003) Cytochrome P450 1B1: A target for inhibition in anticarcinogenesis strategies. Mutat. Res., 523-524, 173-182.
25. Takahashi,E., Fujita,K., Kamataki,T., Arimoto-Kobayashi,S., Okamoto,K. and Negishi,T. (2002) Inhibition of human cytochrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpurin and alizarin. Mutat. Res., 508, 147-156.
26. Chun,Y.J., Kim,S., Kim,D., Lee,S.K. and Guengerich,F.P. (2001) A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis [Erratum (2002) Cancer Res., 62, 1232.]. Cancer Res., 61, 8164-8170.
27. Ciolino,H.P. and Yeh,G.C. (1999) The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor. Br. J. Cancer, 79, 1340-1346.
28. Chen,Z.H., Hurh,Y.J., Na,H.K., Kim,J.H., Chun,Y.J., Kim,D.H., Kang,K.S., Cho,M.H. and Surh,Y.J. (2004) Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis, 25, 2005-2013.
29. Ren,W., Qiao,Z., Wang,H., Zhu,L. and Zhang,L. (2003) Flavonoids: promising anticancer agents. Med. Res. Rev., 23, 519-534.
30. Rocha,S., Campbell,K.J., Roche,K.C. and Perkins,N.D. (2003) The p53-inhibitor pifithrin-alpha inhibits firefly luciferase activity in vivo and in vitro. BMC Mol. Biol., 4, 9.
31. Komarova,E.A., Neznanov,N., Komarov,P.G., Chemov,M.V., Wang,K. and Gudkov,A.V. (2003) p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. J. Biol. Chem., 278, 15465-15468.
32. Culmsee,C., Siewe,J., Junker,V., Retiounskaia,M., Schwarz,S., Camandola,S., El-Metainy,S., Behnke,H., Mattson,M.P. and Krieglstein,J. (2003) Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. J. Neurosci., 23, 8586-8595.
33. Gudkov,A.V. and Komarova,E.A. (2005) Prospective therapeutic applications of p53 inhibitors. Biochem. Biophys. Res. Commun., 331, 726-736.
34. Savouret,J.F. and Quesne,M. (2002) Resveratrol and cancer: A review. Biomed. Pharmacother., 56, 84-87.
35. Donehower,L.A., Harvey,M., Slagle,B.L., McArthur,M.J., Montgomery,C.A.Jr, Butel,J.S. and Bradley,A. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221.